Cargando…
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study
BACKGROUND: Typhoid causes significant mortality among young children in resource-limited settings. Conjugate typhoid vaccines could significantly reduce typhoid-related child deaths, but only one WHO-prequalified typhoid conjugate vaccine exists for young children. To address this gap, we investiga...
Autores principales: | Capeding, Maria Rosario, Sil, Arijit, Tadesse, Birkneh Tilahun, Saluja, Tarun, Teshome, Samuel, Alberto, Edison, Kim, Deok Ryun, Park, Eun Lyeong, Park, Ju Yeon, Yang, Jae Seung, Chinaworapong, Suchada, Park, Jiwook, Jo, Sue-Kyoung, Chon, Yun, Yang, Seon-Young, Ryu, Ji Hwa, Cheong, Inho, Shim, Kyu-Young, Lee, Yoonyeong, Kim, Hun, Lynch, Julia A., Kim, Jerome H., Excler, Jean-Louis, Wartel, T. Anh, Sahastrabuddhe, Sushant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599314/ https://www.ncbi.nlm.nih.gov/pubmed/33150320 http://dx.doi.org/10.1016/j.eclinm.2020.100540 |
Ejemplares similares
-
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report
por: Capeding, Maria Rosario, et al.
Publicado: (2020) -
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose
por: Capeding, Maria Rosario, et al.
Publicado: (2022) -
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age
por: Carlos, Josefina Cadorna, et al.
Publicado: (2022) -
Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children
por: Capeding, Maria Rosario, et al.
Publicado: (2018) -
Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT)
por: Lee, Eun Young, et al.
Publicado: (2020)